INS and Parkinson disease: Although DRD2 agonists generally benefit nutrient metabolism, the use of these drugs is sometimes associated with the development of impulse control disorders, including binge and compulsive eating, in patients with Parkinson's disease, which may lead to excessive weight gain and insulin resistance [74, 75].